{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:40:23Z","timestamp":1774593623285,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Currently, therapeutic management of patients with Graves\u2019 orbitopathy (GO) relies on clinical assessments and MRI. However, monitoring of inflammation remains difficult since external inflammatory signs do not necessarily represent the orbital disease activity. Therefore, we aimed to evaluate the diagnostic value of <jats:sup>18<\/jats:sup>F-FDG-PET\/MRI to assess the inflammation of GO patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Enrolled patients with new onset of GO underwent ophthalmological examinations to evaluate the activity (CAS) and severity of GO (NOSPECS), as well as an <jats:sup>18<\/jats:sup>F-FDG-PET\/MRI (Siemens Biograph mMR) with dual time point imaging (immediately post-injection and 60\u00a0min p.i.). A subset of PET parameters including maximum standardized uptake value (SUVmax), metabolic target volume (MTV), and total lesion glycolysis (TLG) were obtained separately per eye and per extraocular eye muscle (EOM). EOM thickness was measured on the co-registered MRI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 14 enrolled patients, three showed mild, seven moderate-to-severe, and four sight-threatening GO. Patients with severe GO showed statistically significant higher TLG than patients with mild GO (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and higher MTV than patients with mild (<jats:italic>p<\/jats:italic>\u2009=\u20090.03) and moderate (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) GO. Correlation between NOSPECS on one hand and MTV and TLG on the other was significant (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.49\u20130.61).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>TLG and MTV derived from FDG-PET appear to be good discriminators for severe vs. mild-to-moderate GO and show a significant correlation with NOSPECS. As expected, PET parameters of individual eye muscles were not correlated with associated eye motility, since fibrosis, and not inflammation, is mainly responsible for restricted motility. In conclusion, <jats:sup>18<\/jats:sup>F-FDG-PET\/MRI can be used for assessment of GO inflammation.<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00417-021-05339-1","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T09:02:57Z","timestamp":1629277377000},"page":"3107-3117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["18 F-FDG-PET\/MRI in patients with Graves\u2019 orbitopathy."],"prefix":"10.1007","volume":"259","author":[{"given":"Manuel","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Bechrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Antoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Binse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-7689","authenticated-orcid":false,"given":"Michael","family":"Oeverhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"issue":"2","key":"5339_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","volume":"34","author":"SJ Shan","year":"2014","unstructured":"Shan SJ, Douglas RS (2014) The pathophysiology of thyroid eye disease. J Neuroophthalmol 34(2):177\u2013185. https:\/\/doi.org\/10.1097\/WNO.0000000000000132","journal-title":"J Neuroophthalmol"},{"issue":"10","key":"5339_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn RS (2015) Current insights into the pathogenesis of Graves\u2019 ophthalmopathy. Horm Metab Res 47(10):773\u2013778. https:\/\/doi.org\/10.1055\/s-0035-1555762","journal-title":"Horm Metab Res"},{"issue":"6","key":"5339_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/thy.1997.7.885","volume":"7","author":"MN Gerding","year":"1997","unstructured":"Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM (1997) Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 7(6):885\u2013889. https:\/\/doi.org\/10.1089\/thy.1997.7.885","journal-title":"Thyroid"},{"issue":"6","key":"5339_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/edrv-14-6-747","volume":"14","author":"HB Burch","year":"1993","unstructured":"Burch HB, Wartofsky L (1993) Graves\u2019 ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14(6):747\u2013793. https:\/\/doi.org\/10.1210\/edrv-14-6-747","journal-title":"Endocr Rev"},{"issue":"3","key":"5339_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","volume":"152","author":"KA Ponto","year":"2011","unstructured":"Ponto KA, Hommel G, Pitz S, Elflein H, Pfeiffer N, Kahaly GJ (2011) Quality of life in a German Graves orbitopathy population. Am J Ophthalmol 152(3):483-490.e481. https:\/\/doi.org\/10.1016\/j.ajo.2011.02.018","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"5339_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT (2005) Psychosocial morbidity of Graves\u2019 orbitopathy. Clin Endocrinol (Oxf) 63(4):395\u2013402. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02352.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"5339_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1445-5994.1985.tb04021.x","volume":"15","author":"JW Dunne","year":"1985","unstructured":"Dunne JW, Edis RH (1985) Optic nerve involvement in Graves\u2019 ophthalmopathy: a case report and review. Aust N Z J Med 15(2):258\u2013261","journal-title":"Aust N Z J Med"},{"issue":"1","key":"5339_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves O","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves O (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy. Eur Thyroid J 5(1):9\u201326. https:\/\/doi.org\/10.1159\/000443828","journal-title":"Eur Thyroid J"},{"issue":"10","key":"5339_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1055\/s-0043-116945","volume":"49","author":"M Oeverhaus","year":"2017","unstructured":"Oeverhaus M, Witteler T, Lax H, Esser J, Fuhrer D, Eckstein A (2017) Combination therapy of intravenous steroids and orbital irradiation is more effective than intravenous steroids alone in patients with Graves\u2019 orbitopathy. Horm Metab Res 49(10):739\u2013747. https:\/\/doi.org\/10.1055\/s-0043-116945","journal-title":"Horm Metab Res"},{"key":"5339_CR10","doi-asserted-by":"publisher","unstructured":"Eckstein A, Esser J, Oeverhaus M, Saeed P, Jellema HM (2018) Surgical treatment of diplopia in Graves orbitopathy patients. Ophthalmic Plast Reconstr Surg 34 (4S Suppl 1):S75-S84. https:\/\/doi.org\/10.1097\/IOP.0000000000001148","DOI":"10.1097\/IOP.0000000000001148"},{"key":"5339_CR11","doi-asserted-by":"publisher","unstructured":"Eckstein A, Dekowski D, Fuhrer-Sakel D, Berchner-Pfannschmidt U, Esser J (2016) [Graves\u2019 ophthalmopathy]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 113 (4):349\u2013364; quiz 465\u2013346. https:\/\/doi.org\/10.1007\/s00347-016-0239-3","DOI":"10.1007\/s00347-016-0239-3"},{"issue":"4","key":"5339_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marino M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"5339_CR13","doi-asserted-by":"publisher","unstructured":"Boboridis KG, Bunce C (2011) Surgical orbital decompression for thyroid eye disease. The Cochrane database of systematic reviews (12):CD007630. https:\/\/doi.org\/10.1002\/14651858.CD007630.pub2","DOI":"10.1002\/14651858.CD007630.pub2"},{"issue":"6","key":"5339_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218701","volume":"14","author":"M Oeverhaus","year":"2019","unstructured":"Oeverhaus M, Copei A, Mattheis S, Ringelstein A, Tiemessen M, Esser J, Eckstein A, Stahr K (2019) Influence of orbital morphology on proptosis reduction and ocular motility after decompression surgery in patients with Graves\u2019 orbitopathy. PLoS ONE 14(6):e0218701. https:\/\/doi.org\/10.1371\/journal.pone.0218701","journal-title":"PLoS ONE"},{"key":"5339_CR15","doi-asserted-by":"publisher","unstructured":"Uddin JM, Rubinstein T, Hamed-Azzam S (2018) Phenotypes of Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 34 (4S Suppl 1):S28-S33. https:\/\/doi.org\/10.1097\/IOP.0000000000001147","DOI":"10.1097\/IOP.0000000000001147"},{"issue":"4","key":"5339_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/IIO.0000000000000289","volume":"59","author":"VS North","year":"2019","unstructured":"North VS, Freitag SK (2019) A review of imaging modalities in thyroid-associated orbitopathy. Int Ophthalmol Clin 59(4):81\u201393. https:\/\/doi.org\/10.1097\/IIO.0000000000000289","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"5339_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2265.2005.02186.x","volume":"62","author":"CB Terwee","year":"2005","unstructured":"Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM (2005) Measuring disease activity to predict therapeutic outcome in Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 62(2):145\u2013155. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02186.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"5339_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejvs.2010.05.016","volume":"40","author":"JL Bruggink","year":"2010","unstructured":"Bruggink JL, Glaudemans AW, Saleem BR, Meerwaldt R, Alkefaji H, Prins TR, Slart RH, Zeebregts CJ (2010) Accuracy of FDG-PET-CT in the diagnostic work-up of vascular prosthetic graft infection. Eur J Vasc Endovasc Surg 40(3):348\u2013354. https:\/\/doi.org\/10.1016\/j.ejvs.2010.05.016","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"5","key":"5339_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jvs.2005.07.038","volume":"42","author":"K Fukuchi","year":"2005","unstructured":"Fukuchi K, Ishida Y, Higashi M, Tsunekawa T, Ogino H, Minatoya K, Kiso K, Naito H (2005) Detection of aortic graft infection by fluorodeoxyglucose positron emission tomography: comparison with computed tomographic findings. J Vasc Surg 42(5):919\u2013925. https:\/\/doi.org\/10.1016\/j.jvs.2005.07.038","journal-title":"J Vasc Surg"},{"issue":"5","key":"5339_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00259-008-1002-z","volume":"36","author":"M Spacek","year":"2009","unstructured":"Spacek M, Belohlavek O, Votrubova J, Sebesta P, Stadler P (2009) Diagnostics of \u201cnon-acute\u201d vascular prosthesis infection using 18F-FDG PET\/CT: our experience with 96 prostheses. Eur J Nucl Med Mol Imaging 36(5):850\u2013858. https:\/\/doi.org\/10.1007\/s00259-008-1002-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"5339_CR21","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2967\/jnumed.108.053462","volume":"49","author":"J Wasselius","year":"2008","unstructured":"Wasselius J, Malmstedt J, Kalin B, Larsson S, Sundin A, Hedin U, Jacobsson H (2008) High 18F-FDG Uptake in synthetic aortic vascular grafts on PET\/CT in symptomatic and asymptomatic patients. J Nucl Med 49(10):1601\u20131605. https:\/\/doi.org\/10.2967\/jnumed.108.053462","journal-title":"J Nucl Med"},{"key":"5339_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/529187","volume":"2013","author":"L Garcia-Rojas","year":"2013","unstructured":"Garcia-Rojas L, Adame-Ocampo G, Alexanderson E, Tovilla-Canales JL (2013) 18-Fluorodeoxyglucose uptake by positron emission tomography in extraocular muscles of patients with and without Graves\u2019 ophthalmology. J Ophthalmol 2013:529187. https:\/\/doi.org\/10.1155\/2013\/529187","journal-title":"J Ophthalmol"},{"issue":"8","key":"5339_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R (1989) Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol 73(8):639\u2013644","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"5339_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"5339_CR25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2265.2004.02143.x","volume":"61","author":"AK Eckstein","year":"2004","unstructured":"Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG (2004) Clinical results of anti-inflammatory therapy in Graves\u2019 ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 61(5):612\u2013618. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02143.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"5339_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/eje.0.1480491","volume":"148","author":"MF Prummel","year":"2003","unstructured":"Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves\u2019 orbitopathy: the first European Group on Graves\u2019 Orbitopathy experience. Eur J Endocrinol 148(5):491\u2013495","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"5339_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227906","volume":"15","author":"C Deuschl","year":"2020","unstructured":"Deuschl C, Ruber T, Ernst L, Fendler WP, Kirchner J, Monninghoff C, Herrmann K, Quesada CM, Forsting M, Elger CE, Umutlu L (2020) 18F-FDG-PET\/MRI in the diagnostic work-up of limbic encephalitis. PLoS ONE 15(1):e0227906. https:\/\/doi.org\/10.1371\/journal.pone.0227906","journal-title":"PLoS ONE"},{"key":"5339_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaa229","author":"W Gao","year":"2020","unstructured":"Gao W, Gong JN, Guo XJ, Wu JY, Xi XY, Ma ZH, Yang YH, Yang MF (2020) Value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in the evaluation of pulmonary artery activity in patients with Takayasu\u2019s arteritis. Eur Heart J Cardiovasc Imaging. https:\/\/doi.org\/10.1093\/ehjci\/jeaa229","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"5339_CR29","doi-asserted-by":"publisher","unstructured":"Katal S, Gholamrezanezhad A, Nikpanah M, Christensen TQ, Werner TJ, Saboury B, Alavi A, Hess S (2020) Potential applications of PET\/CT\/MR imaging in inflammatory diseases: Part I. Musculoskeletal and gastrointestinal systems. PET Clin. https:\/\/doi.org\/10.1016\/j.cpet.2020.06.008","DOI":"10.1016\/j.cpet.2020.06.008"},{"key":"5339_CR30","doi-asserted-by":"publisher","unstructured":"Langhorst J, Umutlu L, Schaarschmidt BM, Grueneisen J, Demircioglu A, Forsting M, Beiderwellen K, Haubold J, Theysohn JM, Koch AK, Dobos G, Dechene A, Herrmann K, Bruckmann NM, Lauenstein T, Li Y (2020) Diagnostic performance of simultaneous [(18)F]-FDG PET\/MR for assessing endoscopically active inflammation in patients with ulcerative colitis: a prospective study. J Clin Med 9 (8). https:\/\/doi.org\/10.3390\/jcm9082474","DOI":"10.3390\/jcm9082474"},{"issue":"1","key":"5339_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13550-019-0576-8","volume":"9","author":"M de Groot","year":"2019","unstructured":"de Groot M, Patel N, Manavaki R, Janiczek RL, Bergstrom M, Ostor A, Gerlag D, Roberts A, Graves MJ, Karkera Y, Fernando D, Mistry P, Walker A, Wisniacki N, Fryer TD, Jimenez-Royo P (2019) Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand (18)F-GE-180 and comparison with (18)F-FDG and DCE-MRI. EJNMMI Res 9(1):113. https:\/\/doi.org\/10.1186\/s13550-019-0576-8","journal-title":"EJNMMI Res"},{"issue":"1","key":"5339_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40168-018-0478-4","volume":"6","author":"Masetti G, Moshkelgosha S, Kohling HL, Covelli D, Banga JP, Berchner-Pfannschmidt U, Horstmann M, Diaz-Cano S, Goertz GE, Plummer S, Eckstein A, Ludgate M, Biscarini F, Marchesi JR, Consortium I","year":"2018","unstructured":"Masetti G, Moshkelgosha S, Kohling HL, Covelli D, Banga JP, Berchner-Pfannschmidt U, Horstmann M, Diaz-Cano S, Goertz GE, Plummer S, Eckstein A, Ludgate M, Biscarini F, Marchesi JR, Consortium I (2018) Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 6(1):97. https:\/\/doi.org\/10.1186\/s40168-018-0478-4","journal-title":"Microbiome"},{"key":"5339_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/1756-0500-6-353","volume":"6","author":"L Garcia-Rojas","year":"2013","unstructured":"Garcia-Rojas L, Adame-Ocampo G, Mendoza-Vazquez G, Alexanderson E, Tovilla-Canales JL (2013) Orbital positron emission tomography\/computed tomography (PET\/CT) imaging findings in Graves ophthalmopathy. BMC Res Notes 6:353. https:\/\/doi.org\/10.1186\/1756-0500-6-353","journal-title":"BMC Res Notes"},{"issue":"11","key":"5339_CR34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/MNM.0000000000000737","volume":"38","author":"L Uslu-Besli","year":"2017","unstructured":"Uslu-Besli L, Kabasakal L, Sager S, Cicik E, Asa S, Sonmezoglu K (2017) Orbital flourine-18-fluorodeoxyglucose positron emission tomography in patients with Graves\u2019 disease for evaluation of active inflammation. Nucl Med Commun 38(11):964\u2013970. https:\/\/doi.org\/10.1097\/MNM.0000000000000737","journal-title":"Nucl Med Commun"},{"issue":"4","key":"5339_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2967\/jnumed.112.112524","volume":"54","author":"F Jamar","year":"2013","unstructured":"Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, Israel O, Martin-Comin J, Signore A (2013) EANM\/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 54(4):647\u2013658. https:\/\/doi.org\/10.2967\/jnumed.112.112524","journal-title":"J Nucl Med"},{"issue":"4","key":"5339_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.107.048504","volume":"49","author":"NA Mullani","year":"2008","unstructured":"Mullani NA, Herbst RS, O\u2019Neil RG, Gould KL, Barron BJ, Abbruzzese JL (2008) Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. J Nucl Med 49(4):517\u2013523. https:\/\/doi.org\/10.2967\/jnumed.107.048504","journal-title":"J Nucl Med"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05339-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T08:31:51Z","timestamp":1632817911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05339-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5339"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05339-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed under adherence of the ethical foundations of the Declaration of Helsinki and was approved by the Ethics Commission of the University of Essen (11\u20134822-B0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}